Eupraxia Pharmaceuticals (EPRX) Current Leases (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Current Leases of $203510.0 for Q1 2026, up 285.63% year-over-year from $52774.0 in Q1 2025, and up 159.41% quarter-over-quarter from $78452.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Current Leases (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Current Leases for 5 consecutive years, with $203510.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 285.63% year-over-year to $203510.0; the TTM figure through Mar 2026 stood at $203510.0 (up 285.63% YoY), while the FY2025 annual figure was $78452.0, up 9.17% from the prior year.
- Current Leases grew to $203510.0 in Q1 2026 per EPRX's latest filing, from $78452.0 in the prior quarter.
- Across five years, Current Leases topped out at $203510.0 in Q1 2026 and bottomed at $35065.0 in Q2 2025.
- Historically, Current Leases has averaged $77689.4 across 5 years, with a median of $62587.5 in 2023.
- Annual changes were most pronounced in 2023 — Current Leases increased 5.78% — and 2026, when it surged 285.63%.
- Eupraxia Pharmaceuticals' Current Leases stood at $50403.0 in 2022, then rose by 5.78% to $53316.0 in 2023, then soared by 34.78% to $71859.0 in 2024, then increased by 9.17% to $78452.0 in 2025, then jumped by 159.41% to $203510.0 in 2026.
- Business Quant data shows EPRX's Current Leases at $203510.0 in Q1 2026, $78452.0 in Q4 2025, and $76136.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 203,510.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203,510.00 |
| Dec 31, 2025 | 78,452.00 |
| Sep 30, 2025 | 76,136.00 |
| Jun 30, 2025 | 35,065.00 |
| Mar 31, 2025 | 52,774.00 |
| Dec 31, 2024 | 71,859.00 |
| Dec 31, 2023 | 53,316.00 |
| Dec 31, 2022 | 50,403.00 |